HIV Drugs Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	120 Pages	Fortune Business Insights Pvt. Ltd.	September, 2024	FOB19185528

Best Price Guarantee
Price	from $4,850
Length	120 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	September, 2024
SKU	FOB19185528

HIV Drugs Market

Growth Factors of HIV Drugs Market

The HIV drugs market size was valued at USD 34.13 billion in 2023, and the market is now projected to grow from USD 36.11 billion in 2024 to USD 58.24 billion by 2032, exhibiting a CAGR of 6.2% during the forecast period of 2024-2032.

This led to the decline of the market because of the disruptions in the supply chain of HIV drugs and lower patronage in antiretroviral and antibiotic products owing to the COVID-19 pandemic. Moreover, reduced prescriptions of new patients in US, Europe and other COVID affected area also reduced the demand. This volatility affected the global stock and distribution of the necessary drugs amid the pandemic.

Today, researchers and pharmaceutical companies devote more of their attention to HIV drugs and this has boosted these advancements in the recent past. Current market leaders like Gilead Sciences, ViiV Healthcare, and Boehringer Ingelheim are leading such progression due to their investment in new products’ development. These steps seek to cater for the rising need for the newer HIV treatment worldwide.

Current trends in the global market include antiretroviral therapy as long-acting suppression (ATLAS) and availability of the first long-acting injectable formulations. These new ATLAS regimens are in the form of monthly dosages meaning that patients are likely to be more compliant with their therapy.

Comprehensive Analysis of HIV Drugs Market

The HIV drugs market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by product type analysis, and by distribution channel analysis. By product type analysis include combination HIV medicines, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors (NRTIs), and others. By distribution channel analysis include hospital pharmacies, retail pharmacies, online pharmacies, and others.

The North America region lead the HIV drugs market share by benefitting a market size of USD 24.09 billion in 2023 due to the increasing prevalence of HIV infection amongst the U.S. population.

The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.), Boehringer Ingelheim International GmbH, AbbVie Inc., F. Hoffmann-La Roche AG (Genentech, Inc.), Mylan N.V. these market players provide a level-playing competitive landscape.

In December 2023, Zydus Lifesciences Limited received U.S. FDA approval for Darunavir Tablets 600 mg and 800 mg for the treatment of HIV-1 infection.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 6.2% from 2024-2032

Unit Value (USD Billion)

Segmentation By Product Type

- Integrase Inhibitors

- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

- Combination HIV Medicines

- Others

By Distribution Channel

- Hospital Pharmacies

- Retail Pharmacies

- Online Pharmacies

- Others

By Geography

- North America (By Product Type, Distribution Channel, Country)

U.S. (By Product Type)
Canada (By Product Type)

- Europe (By Product Type, Distribution Channel, Country/Sub-Region)

Germany (By Product Type)
France (By Product Type)
U.K. (By Product Type
Italy (By Product Type)
Spain (By Product Type)
Netherlands (By Product Type)
Rest of Europe (By Product Type)

- Asia Pacific (By Product Type, Distribution Channel, Country/Sub-Region)

China (By Product Type)
Japan (By Product Type)
India (By Product Type)
Australia (By Product Type)
Southeast Asia (By Product Type)
Rest of Asia Pacific (By Product Type)

- Rest of the World (By Product Type, Distribution Channel)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Epidemiology of HIV/AIDS, By Key Countries/Regions, 2023; 4.2. Regulatory Scenario by Key Countries/Regions; 4.3. Pipeline Analysis, By Key Players; 4.4. Overview of Current Advances in R&D for HIV Drugs; 4.5. Key Industry Developments – Mergers, Acquisitions, Partnerships etc.; 4.6. New Product Launches, By Key Players; 4.7. Impact of COVID-19 on the Market
5. Global HIV Drugs Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Product Type; 5.1.1. Integrase Inhibitors; 5.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 5.1.3. Combination HIV Medicines; 5.1.4. Others; 5.2. Market Analysis, Insights and Forecast – By Distribution Channel; 5.2.1. Hospital Pharmacies; 5.2.2. Retail Pharmacies; 5.2.3. Online Pharmacies; 5.2.4. Others; 5.3. Market Analysis, Insights and Forecast – By Region; 5.3.1. North America; 5.3.2. Europe; 5.3.3. Asia Pacific; 5.3.4. Rest of the World
6. North America HIV Drugs Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Product Type; 6.1.1. Integrase Inhibitors; 6.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 6.1.3. Combination HIV Medicines; 6.1.4. Others; 6.2. Market Analysis, Insights and Forecast – By Distribution Channel; 6.2.1. Hospital Pharmacies; 6.2.2. Retail Pharmacies; 6.2.3. Online Pharmacies; 6.2.4. Others; 6.3. Market Analysis, Insights and Forecast – By Country; 6.3.1. U.S.; 6.3.1.1. By Product Type; 6.3.2. Canada; 6.3.2.1. By Product Type
7. Europe HIV Drugs Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Product Type; 7.1.1. Integrase Inhibitors; 7.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 7.1.3. Combination HIV Medicines; 7.1.4. Others; 7.2. Market Analysis, Insights and Forecast – By Distribution Channel; 7.2.1. Hospital Pharmacies; 7.2.2. Retail Pharmacies; 7.2.3. Online Pharmacies; 7.2.4. Others; 7.3. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 7.3.1. Germany; 7.3.1.1. By Product Type; 7.3.2. France; 7.3.2.1. By Product Type; 7.3.3. U.K.; 7.3.3.1. By Product Type; 7.3.4. Italy; 7.3.4.1. By Product Type; 7.3.5. Spain; 7.3.5.1. By Product Type; 7.3.6. Netherlands; 7.3.6.1. By Product Type; 7.3.7. Rest of Europe; 7.3.7.1. By Product Type
8. Asia Pacific HIV Drugs Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Product Type; 8.1.1. Integrase Inhibitors; 8.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 8.1.3. Combination HIV Medicines; 8.1.4. Others; 8.2. Market Analysis, Insights and Forecast – By Distribution Channel; 8.2.1. Hospital Pharmacies; 8.2.2. Retail Pharmacies; 8.2.3. Online Pharmacies; 8.2.4. Others; 8.3. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 8.3.1. China; 8.3.1.1. By Product Type; 8.3.2. Japan; 8.3.2.1. By Product Type; 8.3.3. India; 8.3.3.1. By Product Type; 8.3.4. Australia; 8.3.4.1. By Product Type; 8.3.5. Southeast Asia; 8.3.5.1. By Product Type; 8.3.6. Rest of Asia Pacific; 8.3.6.1. By Product Type
9. Rest of the World HIV Drugs Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Product Type; 9.1.1. Integrase Inhibitors; 9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 9.1.3. Combination HIV Medicines; 9.1.4. Others; 9.2. Market Analysis, Insights and Forecast – By Distribution Channel; 9.2.1. Hospital Pharmacies; 9.2.2. Retail Pharmacies; 9.2.3. Online Pharmacies; 9.2.4. Others
10. Competitive Analysis: 10.1. Global Market Share Analysis (2023); 10.2. Company Profiles; 10.2.1. ViiV Healthcare; 10.2.1.1. Overview; 10.2.1.2. Products & Services; 10.2.1.3. SWOT Analysis; 10.2.1.4. Recent Developments; 10.2.1.5. Strategies; 10.2.1.6. Financials (Based on Availability); 10.2.2. Gilead Sciences, Inc.; 10.2.2.1. Overview; 10.2.2.2. Products & Services; 10.2.2.3. SWOT Analysis; 10.2.2.4. Recent Developments; 10.2.2.5. Strategies; 10.2.2.6. Financials (Based on Availability); 10.2.3. GlaxoSmithKline plc; 10.2.3.1. Overview; 10.2.3.2. Products & Services; 10.2.3.3. SWOT Analysis; 10.2.3.4. Recent Developments; 10.2.3.5. Strategies; 10.2.3.6. Financials (Based on Availability); 10.2.4. Merck & Co., Inc.,; 10.2.4.1. Overview; 10.2.4.2. Products & Services; 10.2.4.3. SWOT Analysis; 10.2.4.4. Recent Developments; 10.2.4.5. Strategies; 10.2.4.6. Financials (Based on Availability); 10.2.5. Bristol-Myers Squibb Company; 10.2.5.1. Overview; 10.2.5.2. Products & Services; 10.2.5.3. SWOT Analysis; 10.2.5.4. Recent Developments; 10.2.5.5. Strategies; 10.2.5.6. Financials (Based on Availability); 10.2.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); 10.2.6.1. Overview; 10.2.6.2. Products & Services; 10.2.6.3. SWOT Analysis; 10.2.6.4. Recent Developments; 10.2.6.5. Strategies; 10.2.6.6. Financials (Based on Availability); 10.2.7. Boehringer Ingelheim International GmbH; 10.2.7.1. Overview; 10.2.7.2. Products & Services; 10.2.7.3. SWOT Analysis; 10.2.7.4. Recent Developments; 10.2.7.5. Strategies; 10.2.7.6. Financials (Based on Availability); 10.2.8. AbbVie Inc.; 10.2.8.1. Overview; 10.2.8.2. Products & Services; 10.2.8.3. SWOT Analysis; 10.2.8.4. Recent Developments; 10.2.8.5. Strategies; 10.2.8.6. Financials (Based on Availability); 10.2.9. F. Hoffmann-La Roche AG (Genentech, Inc.); 10.2.9.1. Overview; 10.2.9.2. Products & Services; 10.2.9.3. SWOT Analysis; 10.2.9.4. Recent Developments; 10.2.9.5. Strategies; 10.2.9.6. Financials (Based on Availability); 10.2.10. Mylan N.V.; 10.2.10.1. Overview; 10.2.10.2. Products & Services; 10.2.10.3. SWOT Analysis; 10.2.10.4. Recent Developments; 10.2.10.5. Strategies; 10.2.10.6. Financials (Based on Availability)